GLP-1 injections recalled for sterility concerns

A recall has been issued for 22 vials of compounded Tirzepatide injections by Apothecary Pharma due to concerns over sterility, with the FDA classifying the risk as potentially causing temporary or reversible health effects. The pharmacy, previously warned by the FDA for labeling deficiencies and production practices, faced inspections revealing serious quality issues. This incident highlights ongoing safety concerns related to compounded GLP-1 drugs, which are increasingly used for obesity and diabetes management amid shortages of FDA-approved medications.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل